L33 ANSWER 1 OF 1 WPIDS COPYRIGHT 1999 DERWENT INFORMATION LTD
AN 1989-036766 [05] WPIDS
DNC C89-016232
TI Low releasing buccal compsn. prodn. - by dispersing pharmaceutical in water soluble polymer, adding further polymer mixing and moulding.
DC A96 B07
PA (SANW) SANWA KAGAKU KENKYUSHO CO
CYC 1
PI JP63310817 A 881219 (8905)* 7 pp <--
JP2642354 B2 970820 (9738) 7 pp
ADT JP63310817 A 87JP-0144161 870611; JP2642354 B2 87JP-0144161 870611
FDT JP2642354 B2 Previous Publ. JP63310817
PRAI 87JP-0144161 870611
AN 1989-036766 [05] WPIDS
AB JP63310817 A UPAB: 19930923
Total body-acting pharmaceutical is dispersed in water soluble high polymer substance, further water soluble high polymer substance is added and mixed, followed by moulding the mixt. and prepg. to produce slow-release buccal compsn. to be used by adhering to oral mucosa.
Total body-acting pharmaceuticals (0.1-50 wt.%) may be used to total amt. of compsn. The body acting pharmaceutical is e.g., mono-, di- and tri-nitroglycerin, dinitroisosorbid, Insulin, isoproterenol and proparenol hydrochloride. The high polymer is e.g., hydroxypropyl-cellulose, hydroxypropyl-methylcellulose,CMC, methylcellulose, ethylcellulose, PVA, glucomannane and gum arabic.
ADVANTAGE - Pharmaceutical effect may be maintained for a long time.

L55 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 1999 ACS
AN 1989:639492 HCAPLUS
DN 111:239492
TI Sustained-release buccal pharmaceuticals
IN Kurono, Masatsune; Kojima, Akio; Sato, Makoto; Sugimoto, Manabu; Kosaki, Toshiyuki; Kawamura, Masaki; Sawai, Kiichi
PA Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI JP63310817 | A2 | 19881219 | 87JP-0144161 | 19870611 <-- |
| JP2642354 | B2 | 19970820 | | |

AB A sustained-release buccal formulation is prepd. by dispersing systemic pharmaceuticals in water-sol. polymers such as hydroxypropyl cellulose and poly(vinylpyrrolidone). Thus, 10% trinitroglycerin in hydroxypropyl Me cellulose (I) medium was prepd., and 10 g of this was mixed with 4 g I; 0.3 g $SiO_2$ and 0.7 g Mg stearate were added, and the mixt. was made into buccal tablets (diam. 10 mm, 150 mg/tablet).
IC ICM A61K-009/22
CC 63-6 (Pharmaceuticals)
ST buccal pharmaceutical cellulose ether matrix
IT Pharmaceutical dosage forms
(buccal, sustained-release, matrix for)
IT 55-63-0, Trinitroglycerin 87-33-2, Dinitroisosorbide 318-98-9, Propranolol hydrochloride 7683-59-2, Isoproterenol 9000-01-5, Gum arabic 9002-89-5, Poly(vinyl alcohol) 9003-39-8, Polyvinylpyrrolidone 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethyl cellulose 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9057-02-7, Pullulan 11078-31-2, Glucomannan 27321-61-5, Mononitroglycerin 27321-62-6, Dinitroglycerin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceuticals contg., sustained-release buccal)